Processing

Please wait...

Settings

Settings

Goto Application

1. WO1996008273 - PHARMACEUTICAL COMPOSITIONS CONTAINING D¿2?O

Publication Number WO/1996/008273
Publication Date 21.03.1996
International Application No. PCT/GB1995/002190
International Filing Date 15.09.1995
Chapter 2 Demand Filed 29.03.1996
IPC
A61K 47/02 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
02Inorganic compounds
CPC
A61K 47/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
02Inorganic compounds
Applicants
  • MEDEVA EUROPE LIMITED [GB]/[GB] (AllExceptUS)
  • FURMINGER, Ian, George, Stephen [GB]/[GB] (UsOnly)
  • SIZER, Philip, James [GB]/[GB] (UsOnly)
Inventors
  • FURMINGER, Ian, George, Stephen
  • SIZER, Philip, James
Agents
  • WOODS, Geoffrey, Corlett
Priority Data
9418609.515.09.1994GB
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PHARMACEUTICAL COMPOSITIONS CONTAINING D2O
(FR) COMPOSITIONS PHARMACEUTIQUES CONTENANT DU D2O
Abstract
(EN)
A pharmaceutical composition comprises a solution or suspension of a biological agent in a diluent comprising D2O, which solution or suspension contains sufficient amounts of a sugar, phosphate, glutamic acid or a physiologically acceptable salt thereof and, optionally, a non-toxic protein, a peptone or a mixture of two or more amino acids besides glutamic acid to enhance the stability of the agent. Typically, the composition is a suspension of a live attenuated poliovirus or an inactivated poliovirus of each of poliovirus types 1, 2 and 3. Preferably the solution or suspension contains stabilising amounts of sucrose, KH2PO4, K2HPO4, L-glutamic acid or sodium glutamate and human serum albumin (SPGA).
(FR)
Une compositon pharmaceutique comprend une solution ou une suspension d'un agent biologique dans un diluant comprenant du D2O. Cette solution ou cette suspension contient des quantités suffisantes d'un sucre, de phosphate, d'acide glutamique ou d'un sel physiologiquement acceptable de ces derniers et, éventuellement, une protéine non toxique, un peptone ou un mélange de deux ou plusieurs acides aminés outre de l'acide glutamique pour renforcer la stabilité de l'agent. Généralement, la composition est une suspension d'un poliovirus atténué vivant ou d'un poliovirus inactivé de chacun des types 1, 2, et 3 de poliovirus. De préférence, la solution ou la suspension contient des quantités stabilisantes de sucrose, de KH2PO4, K2HPO4, d'acide L-glutamique ou de glutamate de sodium ou d'albumine sérique de l'homme (SPGA).
Latest bibliographic data on file with the International Bureau